A feature in The American Journal of Managed Care, published 25 September 2026, surveys the regulatory position after the July vote. It reports that the committee recommended six peptides over unanimous objection from the agency's staff scientists, who cited an absence of human clinical data for four of the seven nominees. [1][2]
Oversight of compounding falls mostly to state pharmacy boards. The feature lists Connecticut, Alabama, New York, California, Massachusetts and Louisiana as having moved to restrict peptide compounding, and Texas, Florida, Nevada and Arizona as permissive. More than forty state attorneys general have sent coordinated letters to the FDA raising safety concerns. [1]
Clinicians quoted describe mislabelled products, impurities and immunogenicity as the practical risks of unregulated supply. In the United Kingdom, the medicines regulator opened an investigation into peptide clinics in April 2026. [1][3]
SOURCES
- AJMC. Peptide regulation debate intensifies after FDA advisory panel's controversial vote. 25 Sep 2026. News feature. https://www.ajmc.com/view/peptide-regulation-debate-intensifies-after-fda-advisory-panel-s-controversial-vote
- Health Affairs Forefront. FDA advisory committee's vote may open a drug-compounding back door for unapproved peptides. 2026. Commentary. https://www.healthaffairs.org/content/forefront/fda-advisory-committee-s-vote-may-open-drug-compounding-back-door-unapproved-peptides
- WellFounded. BPC-157 and the difference between an evidence gap and a cover-up (notes the MHRA investigation, Apr 2026). Apr 2026. Secondary summary. https://wellfounded.health/insights/bpc-157-and-the-difference-between-an-evidence-gap-and-a-cover-up
CHANGELOG · 5 Oct 2026 FIRST PUBLISHED · CORRECTIONS ARE ADDED HERE, NEVER HIDDEN